SPONSORED CONTENT
Over the last twelve months, more than 435 healthcare providers across the U.S. had breaches of unsecured protected health information. 73% were hacking/IT incidents with more than 27 million individuals affected. These numbers are according to the U.S. Department of Health and Human Services Office
…
Drug manufacturer Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently apply also to hospitals’ non-340B-purchased “own use” drugs, the group Ryan White Clinics for 340B Access has told its members.
J&J has not responded
…
Federal actuaries predict retail prescription drug spending in the United States will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.
The Centers for Medicare & Medicaid Services (CMS) Office of the Actuary
…
The next period for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin tomorrow, April 1, and end on Friday, April 15.
Eligible hospitals, health centers, clinics, and their child sites and contract pharmacies registered during
…
Charity care has been declining significantly in some Massachusetts hospital systems, raising “a significant policy issue for the 340B program,” a free-market-oriented Massachusetts think tank whose donors include pharmaceutical manufacturers says in a new report.
The state hospital association said
…
The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”
HRSA told BI in a March 29
…
Congress needs to give the U.S. Health Resources and Services Administration (HRSA) comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program, the Biden administration said yesterday in its proposed budget—although it did
…
Arkansas health centers asked a federal court yesterday to let them intervene in the drug industry lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.
Community Health Centers of Arkansas (CHCA) filed the motion yesterday along with
…
Generic-drug manufacturer BioComp is offering covered entities refunds for lower 340B prices that it did not pay on six NDCs for periods over eight years, starting in Q3 2013 and ending in Q2 2021.
BioComp, a wholly-owned subsidiary of San
…
×
*Sign up for news summaries and alerts from 340B Report
